Zacks Research Analysts Reduce Earnings Estimates for Bruker

Key Points

• Zacks Research has lowered its Q3 2025 EPS estimate for Bruker from $0.38 to $0.37, while the consensus full-year earnings estimate stands at $2.69 per share.
• The company recently reported Q2 earnings of $0.32 per share, missing the consensus estimate by $0.01, with revenue of $797.40 million.
• Nisa Investment Advisors LLC significantly increased its stake in Bruker by 377.5%, indicating strong institutional interest despite recent price adjustments from various analysts.

Bruker Corporation (NASDAQ:BRKR - Free Report) - Research analysts at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Bruker in a report released on Friday, September 19th. Zacks Research analyst Team now expects that the medical research company will earn $0.37 per share for the quarter, down from their previous forecast of $0.38. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker's FY2025 earnings at $2.04 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.51 EPS.

BRKR has been the topic of several other research reports. Citigroup cut their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the stock a "hold" rating in a research note on Tuesday, August 5th. Barclays lowered their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Monday, August 4th. Bank of America lowered their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Jefferies Financial Group set a $60.00 price objective on Bruker and gave the stock a "buy" rating in a research note on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $51.30.

Bruker Stock Down 1.2%

NASDAQ:BRKR traded down $0.39 on Monday, hitting $32.78. The stock had a trading volume of 4,604,758 shares, compared to its average volume of 4,791,856. The business's fifty day moving average is $35.03 and its 200 day moving average is $38.33. The company has a market cap of $4.97 billion, a PE ratio of 15.43, a P/E/G ratio of 4.61 and a beta of 1.22. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. Bruker has a 52 week low of $28.53 and a 52 week high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm's revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Insider Activity at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares of the company's stock, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 27.30% of the company's stock.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock valued at $25,000 after purchasing an additional 487 shares during the period. Pinnacle Bancorp Inc. bought a new position in Bruker during the first quarter valued at $29,000. Huntington National Bank grew its holdings in Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after purchasing an additional 645 shares during the period. Allworth Financial LP grew its holdings in Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares during the period. Finally, Spire Wealth Management bought a new position in Bruker during the second quarter valued at $32,000. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.